Compare CASH & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | GLPG |
|---|---|---|
| Founded | 1954 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 1996 | N/A |
| Metric | CASH | GLPG |
|---|---|---|
| Price | $85.93 | $28.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $107.50 | $36.50 |
| AVG Volume (30 Days) | ★ 176.3K | 118.8K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | ★ 18.88 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $839,894,000.00 | N/A |
| Revenue This Year | $7.56 | N/A |
| Revenue Next Year | $6.02 | N/A |
| P/E Ratio | $55.36 | ★ N/A |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $65.93 | $24.74 |
| 52 Week High | $101.26 | $37.78 |
| Indicator | CASH | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 35.03 | 41.03 |
| Support Level | $82.68 | $27.98 |
| Resistance Level | $94.84 | $34.04 |
| Average True Range (ATR) | 3.12 | 0.50 |
| MACD | -1.19 | 0.06 |
| Stochastic Oscillator | 8.83 | 48.72 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.